A pharmaceutical composition containing an Aster koraiensis Nakai extract as an active ingredient, of the present invention, inhibits fat accumulation in liver tissue and treats lobular inflammation, and inhibits ballooning degeneration so as to prevent, alleviate or treat nonalcoholic steatohepatitis.

The present invention relates to a composition for anti-oxidation and anti-inflammation, comprising a Salvia plebeia R. BR. extract and a Centella asiatica extract as an active ingredient. The composition exhibits a radical scavenging ability, and has excellent antioxidant, anti-inflammatory and anti-itching effects by significantly inhibiting inflammation and itch-inducing factors at gene and protein levels, and thus can be advantageously used as a cosmetic composition for anti-oxidation and anti-inflammation.

A method of selectively recovering a hydrophobic target substance. The method is applied to a solution of the target substance in a hydrophobic solvent. An insoluble polysaccharide is combined with the solution, the solution is passed over the insoluble polysaccharide or otherwise exposed to the insoluble polysaccharide. A hydrophilic solvent, which is less hydrophobic than the hydrophobic solvent, is combined with the solution or combined with the hydrophobic target substance and the insoluble polysaccharide after evaporation of the hydrophobic solvent to facilitate binding of the insoluble polysaccharide with the target substance rather than remaining in solution in the hydrophobic solvent. The cyclic polysaccharide is isolated from the solution. A dissociation solvent is combined with the cyclic polysaccharide for solubilizing the target substance from the cyclic polysaccharide and recovering the target substance.

A method for isolating cytisine from plant material includes dissolving the plant material in an alcohol to form a liquid mixture and acidifying the liquid mixture by addition of an acid. The method also includes concentrating the liquid mixture to form a concentrated aqueous solution and extracting the concentrated aqueous solution with a first extractant to form a purified aqueous concentrate. The method includes alkalizing the purified aqueous concentrate with an alkalizing agent to form an alkaline aqueous concentrate. The method further includes extracting the alkaline aqueous concentrate with a second extractant and removing the second extractant to obtain cytisine.

A method for culturing ginseng cell with high content of ginsenoside, including inducing ginseng cell line: after disinfected and sliced, ultrasonically treating old mountain ginseng, and culturing the old mountain ginseng in a culture medium; screening the ginseng cell line: choosing a variety of culture mediums and using hormones for cell separation and culture, selecting cell lines with better growth morphology and faster growth, and performing solid subculture and liquid suspension culture; optimizing conversion conditions: using acids to treat the chosen cell lines, and controlling the treatment temperature and treatment time, detecting ginsenosides Rg3 and Rh2 in the dried products, determining an optimal treatment condition according to the highest total amount; large-scale industrial production: according to the optimal treatment condition, performing the liquid suspension culture of the selected cell lines and scaling up the scale of culture to obtain large-scale industrial production of ginseng cell products.

The present invention relates to a composition for enhancing immunity or a composition for preventing or ameliorating neurodegenerative diseases, both of which contain, as an active ingredient, a mixture extract of goji berries, mulberries and jujubes or an extract mixture thereof.

The present invention relates to a pharmaceutical composition, a pharmaceutical composition for animals, and a food composition, each composition comprising a Scutellaria baicalensis extract, a Liriope platyphylla extract, a Sophora flavescens extract, a Dictamnus root bark extract, and a Phellodendron amurense Ruprecht extract, and preparation methods therefor.

Proposed is a Geumhwagyu extract as an active ingredient. The Geumhwagyu extract of the present disclosure inhibits the differentiation of pre-adipocytes by inducing the degradation of CEBP-α and inhibits the expression of CEBP-α, PPARγ, Perilipin-1, Adiponectin, FABP4, etc., to suppress the accumulation of lipids in adipocytes. It can be easily used as a composition for preventing or managing obesity by inhibiting it and lowering the content of TG (Triacylglycerol) to show anti-obesity activity.

Embodiments of the invention relate to methods for the manufacture of a protein-bound cannabinoid, comprising: obtaining a cannabinoid or cannabis in a form selected from the group consisting of cannabis smoke, cannabis vapor, cannabinoid solution and cannabis extract, and combining the cannabis smoke, vapor, cannabinoid solution or cannabis extract with an aqueous solution or suspension comprising a plasma protein to form a protein-bound cannabinoid. Further embodiments relate to aqueous solutions comprising a plasma protein-bound cannabinoid and pharmaceutical compositions comprising cannabinoids bound to plasma protein.

Disclosed is a composition including, per 100% of its mass: a) 60.0% to 75.0% by mass of an organic solvent (OS.sub.1) chosen from 1,2-propanediol, 1,3-propanediol, 1,4-butanediol, 1,3-butanediol, 1,2-butanediol, 2-methyl-2,4-pentanediol, 1,6-hexanediol, 1,8-octanediol, or a mixture of these compounds; b) 0.1% to 2.0% by mass of a composition (ES) including an amount by mass x.sub.1, expressed as mass equivalent of 1-O-(2-caffeoyl)maloyl-3,5-di-O-catfeoylquinic acid, of greater than or equal to 200 mg/g of a compound of general formula (I):

##STR00001##

in which Q.sub.1, Q.sub.2, Q.sub.3, Q.sub.4 and Q.sub.5 represent, independently of each other, a hydroxyl radical or a salt thereof or a radical chosen from caffeoyl, maloyl, caffeoyl maloyl and maloyl caffeoyl radicals, it being understood that at least one of these radicals Q.sub.1, Q.sub.2, Q.sub.3, Q.sub.4 and Q.sub.5 represents neither the —OH radical nor a salt thereof; and c) 20.0% to 35.0% by mass of water. Related treatments are also disclosed.